MAP2 and Cognitive impairment: Previously, NSTyr had mitigated the cognitive deficits and restored hippocampal levels of the microtubule-associated protein 2 (MAP-2) and the synaptophysin protein in rats subjected to CCH (Lin et al., 2010).